Latest period
$556.00K
YoY change
-98.8%
5Y CAGR
—
Peak year (2024)
$2.08M
Cumulative CapEx
$4.54M
CapEx history chart for Alto Neuroscience (ANRO) from 2021 to 2025
Latest: $24.00K
CapEx growth chart for Alto Neuroscience (ANRO) from 2021 to 2025
Latest: -98.8%
CapEx history table for Alto Neuroscience (ANRO) from 2021 to 2025
| 2025 | $24.00K | -98.8% | −$2.05M | ||
| 2024 | $2.08M | +341.5% | +$1.60M | ||
| 2023 | $470.00K | -35.8% | −$262.00K | ||
| 2022 | $732.00K | +7.6% | +$52.00K | ||
| 2021 | $680.00K | — | — |
- 2025$24.00K-98.8%
- 2024$2.08M+341.5%
- 2023$470.00K-35.8%
- 2022$732.00K+7.6%
- 2021$680.00K—
CapEx values are taken from Alto Neuroscience's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Alto Neuroscience (ANRO)
According to Alto Neuroscience's latest reported financial statements, the company's current CapEx (TTM) is $556.00K. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Alto Neuroscience (ANRO) most recent annual CapEx stands at $24.00K (2025) – plunged 98.8% year-over-year.
Alto Neuroscience CapEx plunged from $2.08M in 2024 to $24.00K in 2025, a 98.8% drawdown.
2024 marks the peak CapEx at $2.08M, with the historical low of $24.00K recorded in 2025.
Alto Neuroscience Capital Expenditures by Year
Alto Neuroscience Capital Expenditures 2025: $24.00K
2025's CapEx for Alto Neuroscience came in at $24.00K, plunged 98.8% below 2024. This figure represents the lowest annual value in the available history.
Alto Neuroscience Capital Expenditures 2024: $2.08M
Alto Neuroscience posted CapEx of $2.08M in 2024, surged 341.5% from 2023. This figure represents the highest annual value in the available history.
Alto Neuroscience Capital Expenditures 2023: $470.00K
In 2023, Alto Neuroscience reported CapEx of $470.00K, plunged 35.8% below 2022.
Alto Neuroscience Capital Expenditures 2022: $732.00K
Alto Neuroscience CapEx in 2022 was $732.00K, grew 7.6% from 2021.
Alto Neuroscience Capital Expenditures 2021: $680.00K
Alto Neuroscience CapEx in 2021 was $680.00K.
See more financial history for Alto Neuroscience (ANRO).
Sector peers by CapEx
Healthcare peers of Alto Neuroscience (ANRO), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Alto Neuroscience (ANRO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation